Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K Current Report on July 24, 2026. The filing addresses Item 5.02 regarding the departure of directors or certain officers and compensatory arrangements. The report details amendments to executive employment agreements for the Chairman, President, and CEO, as well as the Chief Commercial Officer and Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and severance terms.
Material Changes
The Company entered into amended and restated executive employment agreements (the "A&R Agreements") with three key executives to modify severance provisions:
- Troy E. Wilson, Ph.D., J.D. (CEO): Agreement dated July 24, 2026.
- Brian Powl (CCO): Agreement dated July 27, 2026.
- Kathleen Ford (COO): Agreement dated July 27, 2026.
The amendments establish specific severance triggers based on termination without Cause or resignation for Good Reason relative to a "Corporate Transaction."
Guidance, Outlook, and Management Commentary
The filing provides no financial guidance, outlook, or general management commentary. It details the specific financial consequences of executive termination under two scenarios:
- Standard Termination (Outside Corporate Transaction Window):
- CEO: 12 months base salary, 12 months COBRA, and extended option exercise period.
- CCO/COO: 12 months base salary, 12 months COBRA, and extended option exercise period.
- Termination Near Corporate Transaction (Within 59 days prior to or 18 months after closing):
- CEO: 24 months base salary, 200% target bonus, 24 months COBRA, full equity acceleration, and extended option exercise period.
- CCO/COO: 18 months base salary, 150% target bonus, 18 months COBRA, full equity acceleration, and extended option exercise period.
Complete copies of the agreements are scheduled to be filed in the Form 10-Q for the quarter ending September 30, 2026.
Investor Verification Checklist
- Verify the exact definitions of "Cause," "Good Reason," and "Corporate Transaction" in the full agreements filed in the upcoming 10-Q.
- Confirm the current base salaries and target bonus percentages for Dr. Wilson, Mr. Powl, and Ms. Ford to calculate potential severance liabilities.
- Review the Company's current cash position to assess the ability to fund potential lump-sum severance payments if a Corporate Transaction occurs.
- Monitor for any future 8-K filings regarding the actual execution of these severance provisions or changes in executive leadership.